ArticleTherapeutic advances in medical oncology2020

Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis.

Alessandro Rizzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.